What are the treatment regimens for ponatinib (Iclusig) in the treatment of chronic myelogenous leukemia (CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Ponatinib (Iclusig), a pan–BCR-ABL TKI, is approved for patients with any phase of CML (chronic, accelerated, blast) that is resistant or intolerant to prior TKI therapy, including those with the T315I mutation. [22] Because ponatinib poses a high risk for thromboembolic events, its use is restricted to patients for whom no other TKI therapy is indicated. [19]

Ponatinib dose: 45 mg PO daily; continue as long as there is no evidence of disease progression; dosage reduction recommended for coadministration with CYP3A4 inhibitors and toxicities

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!